A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy

Trial Profile

A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Fosaprepitant (Primary) ; Aprepitant; Dexamethasone; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EASE
  • Sponsors Merck & Co
  • Most Recent Events

    • 06 Nov 2012 Planned number of patients changed from 2292 to 2312 as reported by European Clinical Trials Database.
    • 08 Jun 2010 Results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 03 Jun 2010 Primary endpoint 'Complete control of nausea and vomiting' has been met according to a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top